GLPwatch
Papers (10409)
Page 117 of 174, ranked by citation count.
- Unraveling the impact of semaglutide in a diabetic rat model of testicular dysfunction: Insights into spermatogenesis pathways and miRNA-148a-5p.
- Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.
- Epicardial Fat Inflammation and GLP-1/GIP Receptor Analogs: Are we Shifting our Perspective?
- Developing a novel exenatide-based incretin mimic (αB-Ex): Expression, purification and structural-functional characterization.
- Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue.
- Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation.
- Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.
- Exploring the Effect and Mechanism of Liraglutide in Treating Depression Based on Network Pharmacology and Experimental Analysis.
- Evaluating Weight Loss Associated with Bariatric Surgery After Liraglutide Use: A Matched Population-Level Retrospective Cohort Study.
- Is treatment with liraglutide efficient?
- Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge.
- Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
- iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
- Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
- Glucagon-like pepetide-1 receptor agonist suggests novel therapeutic options for hypothalamic obesity.
- A Liraglutide Injection Superimposing a Starvation Acidosis: a Case Report.
- Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment.
- Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet-induced obesity.
- Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
- Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
- Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Obese Polycystic Ovary Syndrome Patients.
- Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- GLP-1 receptor agonists: why is once weekly inferior to once daily?
- Semaglutide and Cardiovascular Outcomes.
- Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
- The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment.
- Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.
- Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis.
- Para-Tyrosine Supplementation Improves Insulin- and Liraglutide- Induced Vasorelaxation in Cholesterol-Fed Rats.
- GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.
- Improvement of liraglutide release from PLGA microspheres by a porous microsphere-gel composite system.
- Successful Treatment of Hypothalamic Obesity with Tirzepatide.
- The mechanistic role of tirzepatide in atherosclerosis: A review.
- Publicising trial results before peer review.
- Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.
- Glycaemic control and weight loss with semaglutide in type 2 diabetes.
- Facilitated structure verification of the biopharmaceutical peptide exenatide by 2D heteronuclear NMR maps.
- Case Report: A case of occult insulinoma localized by [<sup>18</sup>F] FB (ePEG12)12-exendin-4 positron emission tomography with negative findings of selective arterial calcium stimulation test.
- Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita?
- Tirzepatide for diabetes: on track to SURPASS current therapy.
- Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM.
- GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.
- Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates.
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
- Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.
- Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.
- Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
- Weekend therapy in diabetes.
- Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
- HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes.
- Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.
- In patients with HFpEF and obesity, semaglutide increased weight loss and reduced symptoms and physical limitations at 52 wk.
- Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
- Semaglutide Improved Cardiovascular Health in People Without Diabetes.
- Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States.
- Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.